Iressa News and Research

RSS
Gefitinib shows promise in Chinese lung cancer patients

Gefitinib shows promise in Chinese lung cancer patients

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Pfizer’s XALKORI now available in Canada

Pfizer’s XALKORI now available in Canada

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis commences CO-1686 Phase I/II study in NSCLC

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO receives USAN, WHO generic name approval for ficlatuzumab

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

Targeted therapies could treat a broad range of cancers: Research

Targeted therapies could treat a broad range of cancers: Research

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

CancerDrugsDirect.com provides customers access to affordable cancer medications

CancerDrugsDirect.com provides customers access to affordable cancer medications